The use of regenerative medicine in the management of invasive bladder cancer

Matthew E. Hyndman, Deborah Kaye, Nicholas C. Field, Keith A. Lawson, Norm D. Smith, Gary D. Steinberg, Mark P. Schoenberg, Trinity J. Bivalacqua

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel technologies for creating a urinary diversion without the use of intestine. Clinical trials using neourinary conduits (NUC) seeded with autologous smooth muscle cells are currently in progress and may represent a significant surgical advance, potentially eliminating the complications associated with the use of gastrointestinal segments in the urinary reconstruction, simplifying the surgical procedure, and greatly facilitating recovery from cystectomy.

Original languageEnglish (US)
Article number653652
JournalAdvances in Urology
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Urinary Diversion
Regenerative Medicine
Urinary Bladder Neoplasms
Cystectomy
Morbidity
Large Intestine
Small Intestine
Smooth Muscle Myocytes
Intestines
Urinary Bladder
Clinical Trials
Technology
Muscles

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Urology

Cite this

Hyndman, M. E., Kaye, D., Field, N. C., Lawson, K. A., Smith, N. D., Steinberg, G. D., ... Bivalacqua, T. J. (2012). The use of regenerative medicine in the management of invasive bladder cancer. Advances in Urology, [653652]. https://doi.org/10.1155/2012/653652

The use of regenerative medicine in the management of invasive bladder cancer. / Hyndman, Matthew E.; Kaye, Deborah; Field, Nicholas C.; Lawson, Keith A.; Smith, Norm D.; Steinberg, Gary D.; Schoenberg, Mark P.; Bivalacqua, Trinity J.

In: Advances in Urology, 2012.

Research output: Contribution to journalArticle

Hyndman, ME, Kaye, D, Field, NC, Lawson, KA, Smith, ND, Steinberg, GD, Schoenberg, MP & Bivalacqua, TJ 2012, 'The use of regenerative medicine in the management of invasive bladder cancer', Advances in Urology. https://doi.org/10.1155/2012/653652
Hyndman ME, Kaye D, Field NC, Lawson KA, Smith ND, Steinberg GD et al. The use of regenerative medicine in the management of invasive bladder cancer. Advances in Urology. 2012. 653652. https://doi.org/10.1155/2012/653652
Hyndman, Matthew E. ; Kaye, Deborah ; Field, Nicholas C. ; Lawson, Keith A. ; Smith, Norm D. ; Steinberg, Gary D. ; Schoenberg, Mark P. ; Bivalacqua, Trinity J. / The use of regenerative medicine in the management of invasive bladder cancer. In: Advances in Urology. 2012.
@article{9aab69e28e1246a0802e483395c76c1d,
title = "The use of regenerative medicine in the management of invasive bladder cancer",
abstract = "Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel technologies for creating a urinary diversion without the use of intestine. Clinical trials using neourinary conduits (NUC) seeded with autologous smooth muscle cells are currently in progress and may represent a significant surgical advance, potentially eliminating the complications associated with the use of gastrointestinal segments in the urinary reconstruction, simplifying the surgical procedure, and greatly facilitating recovery from cystectomy.",
author = "Hyndman, {Matthew E.} and Deborah Kaye and Field, {Nicholas C.} and Lawson, {Keith A.} and Smith, {Norm D.} and Steinberg, {Gary D.} and Schoenberg, {Mark P.} and Bivalacqua, {Trinity J.}",
year = "2012",
doi = "10.1155/2012/653652",
language = "English (US)",
journal = "Advances in Urology",
issn = "1687-6369",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The use of regenerative medicine in the management of invasive bladder cancer

AU - Hyndman, Matthew E.

AU - Kaye, Deborah

AU - Field, Nicholas C.

AU - Lawson, Keith A.

AU - Smith, Norm D.

AU - Steinberg, Gary D.

AU - Schoenberg, Mark P.

AU - Bivalacqua, Trinity J.

PY - 2012

Y1 - 2012

N2 - Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel technologies for creating a urinary diversion without the use of intestine. Clinical trials using neourinary conduits (NUC) seeded with autologous smooth muscle cells are currently in progress and may represent a significant surgical advance, potentially eliminating the complications associated with the use of gastrointestinal segments in the urinary reconstruction, simplifying the surgical procedure, and greatly facilitating recovery from cystectomy.

AB - Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel technologies for creating a urinary diversion without the use of intestine. Clinical trials using neourinary conduits (NUC) seeded with autologous smooth muscle cells are currently in progress and may represent a significant surgical advance, potentially eliminating the complications associated with the use of gastrointestinal segments in the urinary reconstruction, simplifying the surgical procedure, and greatly facilitating recovery from cystectomy.

UR - http://www.scopus.com/inward/record.url?scp=84866252559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866252559&partnerID=8YFLogxK

U2 - 10.1155/2012/653652

DO - 10.1155/2012/653652

M3 - Article

JO - Advances in Urology

JF - Advances in Urology

SN - 1687-6369

M1 - 653652

ER -